

Challenges that impact care


Drug costs are rising faster than ever

- High costs threaten patient access to critical treatments, increase patient out-of-pocket expenses, and create additional financial burden for hospitals and patients.
- Drug companies are:
 - increasing prices for age-old brand name and generic drugs; often 2 or 3 times each year, with no forewarning or expectation of increases from the marketplace.
 - designating products for a higher cost specialty distribution channel with no reasonable basis for such designation.
- Increases often seem to be in controlled markets and focused on mature products where little competition remains.

© 2015 The Resource Group

THE RESOURCE GROUP®
Integrating Excellence and Stewardship

BRAND DRUGS	2014	2015	REAL IMPACT ON AVAILABLE CARE DOLLARS	INCREASE	GENERIC DRUGS	2014	2015	REAL IMPACT ON AVAILABLE CARE DOLLARS	INCREASE
MIACALCIN Used to reduce high blood levels of calcium as well as treating certain bone problems such as Paget's disease.	\$60.00	\$1,880.00	\$3,900,000	3,033%	PROCTOSOL-HC CREAM Used for the treatment of minor pain, itching, swelling and discomfort caused by hemorrhoids.	\$3.00	\$54.00	\$145,000	1,700%
ISUPREL Used in mild and serious episodes of heart block and cardiac arrest	\$2,060.00	\$17,000.00	\$6,800,000	725%	POTASSIUM CHLORIDIE ORAL SOL Treatment or prevention of hypokalemia	\$25.00	\$350.00	\$270,000	1,300%
BLOXIVERZ Used to reverse effects of neuromuscular blocking agents after surgery	\$130.00	\$880.00	\$2,100,000	501%	VASOPRESSIN Used to increase blood pressure in adults in shock as well as treat symptoms of diabetes insipidus and certain conditions of the stomach after surgery.	\$89.00	\$875.00	\$490,000	880%
NITROPRESS Used for the immediate reduction of blood pressure in hypertensive crisis.	\$200.00	\$833.00	\$5,100,000	317%	SODIUM PHOSPHATE Used for the treatment of Hypophosphatemia	\$58.00	\$437.00	\$200,000	650%
EDECRIN Used in the treatment of edema associated with congestive heart failure	\$1,510.00	\$3,780.00	\$760,000	150%	MITOMYCIN Use for the treatment of cancer.	\$185.00	\$947.00	\$448,000	412%
or cirrhosis of the liver. MEPHYTON Used in the treatment of bleeding problems caused by low vitamin K blood levels.	\$1,930.00	\$4,830.00	\$450,000	150%	EPHEDRINE Used as a decongestant and bronchodilator for the temporary relief of shortness of breath, chest tightness and wheezing due to bronchial asthma	\$102.00	\$331.00	\$825,000	225%
ONCASPAR Used as part of a multi-agent chemotherapeutic regimen for the treatment of Lymphoblastic Luekemia	\$5,900.00	\$13,300.00	\$1,100,000	125%	FLUCYTO SINE Used for the treatment of serious fungal infections of the blood, lungs, heart, central nervous system, and urinary tract	\$3,400.00	\$11,000.00	\$270,000	224%
EPIPEN Used to treat severe allergic reactions, including anaphylaxis in emergency situations.	\$290.00	\$440.00	\$280,000	52%	METHYLENE BLUE Used for the treatment of infections, pathologies or poisoning and as a dye for diagnostics.	\$455.00	\$1,315.00	\$516,000	189%
GLUCAGEN Used to treat severe hypoglycemia.	\$110.00	\$160.00	\$400,000	45%	KETOROLAC TROMETHAMINE Non-steroidal anti-inflammatory used to treat pain and inflammation	\$16.00	\$30.00	\$206,000	88%
HUMIRA Used as a treatment for a variety of conditions including rheumatoid and psontatic arthritis, ankylosing spondyttis, Crohn's Disease and ulcerative colitis.	\$2,370.00	\$3,030.00	\$430,000	28%	SUCCINYLCHOLINE CHLORIDE As an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery	\$235.00	\$367.00	\$425,000	56%
* Drug.com and RxList.com were among the	sources utilized	for the drug use d	escriptions on this slide			_ ^	Tire Dr	SOURCE G F	OUD.



How we are responding

Transformational work



Created a joint physician, pharmacist, nursing and administrative leader group to determine evidencebased, safe and costeffective use of alternatives



Developing a national formulary to reduce unnecessary variation across the organization which focuses on patient and clinician needs – not drug supplier marketing efforts.



Launched a national initiative that will further increase time for clinical pharmacists to assist the safe therapeutic exchange of drugs.

© 2015 The Resource Group



